Author

Luisa Roberts

Observed name: L. Roberts

Institution: Genentech

Observed institutions: Mayo Clinic, Pfizer (United States), Genentech, University of Michigan, Moffitt Cancer Center, Royal Marsden Hospital

OpenAlex ID: A5032651541

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

2007 · Johann S. de Bono, Gerhardt Attard, et al. · Clinical Cancer Research · 192

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

2018 · J. Bendell, F. Ciardiello, et al. · Annals of Oncology · 50

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin’s lymphoma

2001 · A. Tulpule, M.U. Rarick, et al. · Annals of Oncology · 19

Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors.

2007 · David Olmos, R. Molife, et al. · Molecular Cancer Therapeutics · 8

Phase 1 first-in-human dose escalation study of cp-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor

2006 · M. Lacy, M. Alsina, et al. · Journal of Clinical Oncology · 6

Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.

2007 · Martha Q. Lacy, Melissa Alsina, et al. · Blood · 5

Works count: 6

Citation count: 280

H-index: 5

I10-index: 3